Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Ocugen Inc
OCGN | US
0.94
USD-0.00
-0.17%
OCGN | US
About Ocugen Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.94
Open
0.95
High
0.97
Low
0.93
Ocugen Inc. a clinical-stage biopharmaceutical company focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400 a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200 a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema diabetic retinopathy and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern Pennsylvania.
View LessOCGN | US
Risk
52.8
Sharpe
1.17
Luna's Score
39/100
Recommendation
Sell
Luna says (OCGN | US)
What's Working
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
32.4%1 month
52.8%3 months
66.8%6 months
85.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
15.22
Price to book
15.82
Debt to equity
0.41
Debt to assets
0.17
Ent. to EBITDA
-1.95
Ent. to rev.
35.65
PEG
-
Other Fundamentals
EBITDA
-50.51M
MarketCap
270.13M
MarketCap(USD)
270.13M
Div. yield
-
Op. margin
-1.35K
Erngs. growth
-
Rev. growth
135.30
Ret. on equity
-114.42
Short ratio
13.03
Short perc.
17.89
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.12
Range1M
0.21
Range3M
0.81
Volumes: Market Activity
Rel. volume
0.53
Price X volume
1.62M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.95 | - | Cheaper |
| Ent. to Revenue | 35.65 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 15.82 | 15.55 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 66.84 | - | Par |
| Debt to Equity | 0.41 | -1.23 | Expensive |
| Debt to Assets | 0.17 | 0.25 | Cheaper |
| Market Cap | 270.13M | - | Emerging |
